Entering text into the input field will update the search result below

European advisory group backs Roche's Tecentriq in first-line liver cancer

Sep. 18, 2020 9:46 AM ETRoche Holding AG (RHHBY) StockRHHBYBy: Douglas W. House, SA News Editor
  • The European Medicines Agency's advisory group CHMP has adopted a positive opinion backing the use of Roche's (OTCQX:RHHBY +1.4%) Tecentriq (atezolizumab), combined with Avastin (bevacizumab), for the treatment of adults with advanced or unresectable hepatocellular carcinoma in a first-line setting.
  • The PD-L1 inhibitor is currently approved in Europe for the treatment of urothelial, non-small cell lung, small cell lung and breast cancers.
  • A final decision from the European Commission usually takes ~60 days.

Recommended For You

More Trending News

About RHHBY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
RHHBY--
Roche Holding AG